Search

Your search keyword '"Buti, María"' showing total 512 results

Search Constraints

Start Over You searched for: Author "Buti, María" Remove constraint Author: "Buti, María"
512 results on '"Buti, María"'

Search Results

1. Stratified analyses refine association between TLR7 rare variants and severe COVID-19

2. Implementing a new HCV model of care for people who use drugs

4. Sex and ethnic disparities in hepatitis B evaluation and treatment across the world

5. Joint host-pathogen genomic analysis identifies hepatitis B virus mutations associated with human NTCP and HLA class I variation

6. Tenofovir Disoproxil Fumarate Reduces the Severity of COVID-19 in Patients with Chronic Hepatitis B

10. Hepatocellular carcinoma risk in sub-Saharan African and Afro-Surinamese individuals with chronic hepatitis B living in Europe

11. Sequential Peg-IFN after bepirovirsen may reduce post-treatment relapse in chronic hepatitis B

14. Characterizing Hepatitis Delta in Spain and the gaps in its management

15. Integrating viral hepatitis management into the emergency department: A further step towards viral hepatitis elimination

16. PAGE-B incorporating moderate HBV DNA levels predicts risk of HCC among patients entering into HBeAg-positive chronic hepatitis B

17. HBV DNA and HBsAg Levels at 24 Weeks Off-Treatment Predict Clinical Relapse and HBsAg Loss in HBeAg-Negative Patients Who Discontinued Antiviral Therapy

19. mTOR inhibitors a potential predisposing factor for chronic hepatitis E: Results from the prospective collaborative CHES study (Chronic Hepatitis EScreening in patients with immune impairment and increased transaminases levels)

21. Tenofovir alafenamide and tenofovir disoproxil fumarate reduce incidence of hepatocellular carcinoma in patients with chronic hepatitis B

23. Global prevalence, cascade of care, and prophylaxis coverage of hepatitis B in 2022: a modelling study

24. Long-term follow-up of HCV-infected patients with end-stage chronic kidney disease after sustained virological response with direct-acting antiviral therapy

25. Hepatitis D virus infection: Pathophysiology, epidemiology and treatment. Report from the first international delta cure meeting 2022

26. Efficacy and safety of the siRNA JNJ-73763989 and the capsid assembly modulator JNJ-56136379 (bersacapavir) with nucleos(t)ide analogues for the treatment of chronic hepatitis B virus infection (REEF-1): a multicentre, double-blind, active-controlled, randomised, phase 2b trial

29. Lower pretreatment HBV DNA levels are associated with better off-treatment outcomes after nucleo(s)tide analogue withdrawal in patients with HBeAg-negative chronic hepatitis B: A multicentre cohort study

31. Hepatitis D double reflex testing of all hepatitis B carriers in low-HBV- and high-HBV/HDV-prevalence countries

33. Intrahepatic quantification of HBV antigens in chronic hepatitis B reveals heterogeneity and treatment-mediated reductions in HBV core-positive cells

35. Recomendaciones para el diagnóstico integral de las hepatitis virales crónicas en una única extracción analítica

39. A Global Survey of Physicians Knowledge About Nonalcoholic Fatty Liver Disease

40. Global change in hepatitis C virus prevalence and cascade of care between 2015 and 2020: a modelling study

43. Prediction of Sustained Response After Nucleo(s)tide Analogue Cessation Using HBsAg and HBcrAg Levels: A Multicenter Study (CREATE)

45. Enhancing linkage to care for hepatitis B, D, and C patients: A retrospective‐prospective study.

48. Characterization of the liver immune microenvironment in liver biopsies from patients with chronic HBV infection

49. The EASL–Lancet Liver Commission: protecting the next generation of Europeans against liver disease complications and premature mortality

Catalog

Books, media, physical & digital resources